NeuBase Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

NeuBase Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-0.1%

Buyback Yield

Total Shareholder Yield	-0.1%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

May 12

Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?

Jan 24

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Oct 02

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Jun 02

Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?

Feb 23

We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth

Jan 19

NeuBase Therapeutics EPS in-line

Dec 23

NeuBase Therapeutics reports encouraging data for PATrOL-enabled anti-gene in a type of muscular dystrophy

Dec 16

Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?

Dec 15

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if NBSE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NBSE's dividend payments have been increasing.

Dividend Yield vs Market

NeuBase Therapeutics Dividend Yield vs Market

How does NBSE dividend yield compare to the market?
Segment	Dividend Yield
Company (NBSE)	n/a
Market Bottom 25% (US)	1.3%
Market Top 25% (US)	4.2%
Industry Average (Biotechs)	2.3%
Analyst forecast (NBSE) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate NBSE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NBSE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate NBSE's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NBSE has not reported any payouts.

NeuBase Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

NeuBase Therapeutics Files Form 15

NeuBase Therapeutics, Inc.(NasdaqCM:NBSE) dropped from S&P TMI Index

New major risk - Financial data availability

The Nasdaq Stock Market LLC Notifies NeuBase Therapeutics Regarding Non-Compliance with the Minimum Bid Price Requirement and Ineligible for a Second 180 Calendar Day Period to Regain Compliance

NeuBase Therapeutics, Inc. Announces CEO Changes

New minor risk - Financial data availability

NeuBase Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Neubase Therapeutics, Inc. Announces Franklyn G. Prendergast Board of Directors Passed Away

New major risk - Shareholder dilution

NeuBase Therapeutics, Inc., Annual General Meeting, Sep 28, 2023

High number of new and inexperienced directors

NeuBase Therapeutics, Inc. announced that it has received $3.512751 million in funding

NeuBase Therapeutics, Inc. Presents Non-Human Primate Data Illustrating Stealth Editors Are Non-Immunogenic, Opening the Door to Redosing

Neubase Therapeutics, Inc. Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors

NeuBase Therapeutics, Inc. Announces Resignation of Eric J. Ende as Board of Director

NeuBase Therapeutics, Inc. Announces Formation of Gene Editing Advisory Board

Price target decreased to US$10.00

NeuBase Therapeutics, Inc. Announces Resignation of William Mann as President and Chief Operating Officer, Effective October 31, 2022

NeuBase Therapeutics, Inc. to Reduces its Workforce by Approximately 60%

NeuBase Therapeutics, Inc. Announces Executive Changes

Price target decreased to US$10.67

NeuBase Therapeutics Receives Non-Compliance Letter from Nasdaq

Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?

NeuBase Therapeutics GAAP EPS of -$0.26 beats by $0.04

NeuBase Therapeutics, Inc., Annual General Meeting, Sep 08, 2022

NeuBase Therapeutics, Inc. Announces Promotion of William Mann to President

NeuBase Therapeutics promotes Dr. William Mann to President and COO

NeuBase Therapeutics, Inc. Presents New Preclinical Data At ASGCT 2022 for Its Dm1 Program Demonstrating Wide Tissue Distribution and Supporting Differentiated Whole-Body Treatment Solution

We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

Price target decreased to US$14.67

High number of new and inexperienced directors

Price target decreased to US$14.67

Price target decreased to US$15.50

Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?

CFO, Treasurer & Secretary Samuel Backenroth has left the company

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

NeuBase Therapeutics, Inc.(NasdaqCM:NBSE) dropped from Russell 3000E Index

NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor Growth

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Independent Director has left the company

Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?

Price target raised to US$17.00

New 90-day high: US$11.66

New 90-day high: US$10.08

We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth

New 90-day low: US$7.27

NeuBase Therapeutics EPS in-line

NeuBase Therapeutics Announces Positive Preclinical in Vivo Data for Patrol Enabled Anti-Gene for the Treatment of Myotonic Dystrophy Type 1

NeuBase Therapeutics reports encouraging data for PATrOL-enabled anti-gene in a type of muscular dystrophy

Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?

NeuBase Therapeutics Announces Appointment of Curt Bradshaw as Chief Scientific Officer

NeuBase Therapeutics Announces Addition of Eriks Rozners and Randy Davis to Scientific Advisory Board

NeuBase Therapeutics, Inc. Announces Addition of Peter Nielsen, Ph.D., Inventor of Peptide Nucleic Acid Technology, to Scientific Advisory Board

NeuBase Therapeutics, Inc. Enters into Lease Agreement with 350 Technology Drive Partners, LLC

New 90-day low - US$7.46

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies